Diagnosis and management of osteoporosis in inflammatory bowel disease

Minerva Medica

Volumn 95, Issue 6, 2004, Pages 481-487

  Reinshagen, M ^a   Von Tirpitz, C ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Inflammatory bowel diseases, diagnosis; Inflammatory bowel diseases, therapy; Osteoporosis

Indexed keywords

GLUCOCORTICOID;

BONE DENSITY; ENTERITIS; HUMAN; MALABSORPTION; OSTEOPOROSIS; REVIEW;

BONE DENSITY; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALABSORPTION SYNDROMES; OSTEOPOROSIS;

EID: 18444372042     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Votta BJ, Bertolini DR. Cytokine suppressive anti-inflammatory componds inhibit bone resorption in vitro. Bone 1994;15:533-8.
2. Hofbauer LC, Heufelder AE. Osteoprotegerin: a novel local player in bone metabolism. Eur J Endocrinol 1997;137:345-6.
3. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999;141:195-210.
4. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-13.
5. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:857-64.
6. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-9.
7. von Tirpitz C, Epp S, Klaus J, Mason RA, Hawa G, Brinskelle-Schmal N et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003;15:1165-70.
8. von Tirpitz C, Steder-Neukamm U, Glas K, Sander S, Ring C, Klaus J et al. [Osteoporose bei chronisch entzündli-chen Darmerkrankungen - Ergebnisse einer Umfrage bei Mitgliedern der Deutschen M. Crohn und colitis ulcerosa Vereinigung (DCCV)]. Z Gastroenterol 20O3;41: 1145-50.
9. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Mühlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-63.
10. Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;15:1267-73.
11. Lukert B, Kream BE. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezkian JP, Raisz LG, Rodan GA, editors. Priciples of bone biology. New York: Academic Press; 1996.p.533-48.
12. Schaison G, Durand F, Mowszowicz I. Effect of glucocorticoids on plasma testosterone in men. Acta Endocrinol (Copenh) 1978;89:126-31.
13. Lukert B, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
14. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
15. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996;31:367-71.
16. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995;7:609-14.
17. Vogelsang H, Klamert M, Resch H, Ferenci P. Dietary vitamin D intake in patients with Crohn's disease. Wien Klin Wochenschr 1995;107:578-81.
18. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
19. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247-55.
20. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:192-9.
21. von Tirpitz C, Pischuiti G, Klaus J, Rieber A, Bruckel J, Böhm BO et al. Pathological bone density in chronic inflammatory bowel diseases. Prevalence and risk factors. Z Gastroenterol 1999;37:5-12.
22. von Tirpitz C, Kohn C, Steinkamp M, Geerling I, Maier V, Möller P et al. Lactose intolerance in active Crohn's disease. Clinical value of duodenal lactase analysis. J Clin Gastroenterol 2002;34:49-53.
23. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis [see comments]. Gastroenterol 1994;107:1031-9.
24. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999;34:696-702.
25. Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999;94:1292-7.
26. Bernstein CN, Leslie W, Leboff HS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastro-enterol 2003;124:795-841.
27. Hoppin AG, Kaplan LM, Zurakowski D, Leichtner AM, Bousvaros A. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;26:500-5.
28. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999;34:696-702.
29. Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralisation and growth retardation inflammatory bowel disease. Invest Radiol 1976;11:541-9.
30. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
31. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
32. Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G et al. High prevalence of vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-8.
33. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
34. von Tirpitz C, Klaus J, Steinkamp M, Mason R, Kratzer W, Adler G et al. Quantitative ultrasound of the proximal phalanges and dual energy x-ray absorptiometry in Crohn's disease patients with osteopenia. J Gastroenterol 2003;38:238-43.
35. Adachi JD, Ioannidis G. Calcium and vitamin D therapy in corticosteroid-induced bone loss. What is the evidence? Calcif Tissue Int 1999;65:332-6.
36. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
37. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year ranomized clinical trial. JAMA 1999;282:637-45.
38. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000;11:727-38.
39. von Tirpitz C, Klaus J, Brückel J, Rieber A, Regeniter A, Boehm BO et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000;12:19-24.
40. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998;8:4-12.
41. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
42. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R et al. Therapy of osteoporosis in patients with Crohn's disease. A randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003;17:807-16.
43. Russell RG, Rogers MJ. Bisphosphonates:from the laboratory to the clinic and back again. Bone 1999;25:97-106.
44. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
45. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
46. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
47. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2004;16:348-60.